- Home
- MESO vs GAM Comparison
MESO vs GAM Comparison
Compare MESO & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- GAM
- Stock Information
- Founded
- MESO 2004
- GAM 1927
- Country
- MESO Australia
- GAM United States
- Employees
- MESO N/A
- GAM N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- GAM Investment Managers
- Sector
- MESO Health Care
- GAM Finance
- Exchange
- MESO Nasdaq
- GAM Nasdaq
- Market Cap
- MESO 1.3B
- GAM 1.4B
- IPO Year
- MESO N/A
- GAM N/A
- Fundamental
- Price
- MESO $18.41
- GAM $62.84
- Analyst Decision
- MESO Buy
- GAM
- Analyst Count
- MESO 2
- GAM 0
- Target Price
- MESO $24.00
- GAM N/A
- AVG Volume (30 Days)
- MESO 283.4K
- GAM 20.1K
- Earning Date
- MESO 08-28-2025
- GAM 01-01-0001
- Dividend Yield
- MESO N/A
- GAM 5.74%
- EPS Growth
- MESO N/A
- GAM N/A
- EPS
- MESO N/A
- GAM 11.67
- Revenue
- MESO $17,198,000.00
- GAM N/A
- Revenue This Year
- MESO $288.50
- GAM N/A
- Revenue Next Year
- MESO $173.73
- GAM N/A
- P/E Ratio
- MESO N/A
- GAM $3.95
- Revenue Growth
- MESO 191.39
- GAM N/A
- 52 Week Low
- MESO $7.09
- GAM $37.32
- 52 Week High
- MESO $22.00
- GAM $46.48
- Technical
- Relative Strength Index (RSI)
- MESO 70.00
- GAM 73.79
- Support Level
- MESO $15.60
- GAM $61.56
- Resistance Level
- MESO $16.19
- GAM $62.75
- Average True Range (ATR)
- MESO 0.54
- GAM 0.85
- MACD
- MESO 0.17
- GAM 0.00
- Stochastic Oscillator
- MESO 86.95
- GAM 85.03
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.